Article

Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid using mass spectrometry-based proteomics

2023-10-07

Abstract excerpt

<h4>ABSTRACT</h4> Progressive supranuclear palsy (PSP) is a neurodegenerative disorder that is often misdiagnosed as Parkinson’s Disease (PD) because of shared symptoms. PSP is characterized by the accumulation of tau protein in specific brain regions, which results in loss of balance, gaze impairment, and dementia. Diagnosing PSP is often challenging, and there’s a significant demand for reliable biomarkers. How...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 61808834-526d-500c-b1fc-f9bf470b7e40
DOI: 10.1101/2023.10.05.561075

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid using mass spectrometry-based proteomicsDOI 10.1101/2023.10.05.561075Read

Mass spectrometry‐based proteomics analysis of human globus pallidus from progressive supranuclear palsy patients discovers multiple disease pathwaysSemantic proximity Read

CSF Proteomics in Patients With Progressive Supranuclear PalsySemantic proximity Read

The diagnosis of progressive supranuclear palsy: current opinions and challenges.Semantic proximity Read

Identification of phosphorylated tau protein interactors in progressive supranuclear palsy ( PSP ) reveals networks involved in protein degradation, stress response, cytoskeletal dynamics, metabolic processes, and neurotransmissionSemantic proximity Read

A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsySemantic proximity Read

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.Semantic proximity Read

Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s diseaseSemantic proximity Read

Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal DementiaSemantic proximity Read

Discovery and validation of biomarkers for Parkinson’s disease from human cerebrospinal fluid using mass spectrometry-based proteomics analysisSemantic proximity Read

Network Analysis of the Cerebrospinal Fluid Proteome Reveals Shared and Unique Differences Between Sporadic and Familial Forms of Amyotrophic Lateral SclerosisSemantic proximity Read

The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of ProteomicsSemantic proximity Read

Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment.Semantic proximity Read